Search Results - "O'CONNOR, P. W"

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis by O'CONNOR, P. W, GOODMAN, A, KAPPOS, L, LUBLIN, F. D, MILLER, D. H, POLMAN, C, RUDICK, R. A, ASCHENBACH, W, LUCAS, N

“…Due to a heightened risk of progressive multifocal leukoencephalopathy (PML) with increased natalizumab exposure, some physicians interrupt treatment of…”
Get full text

Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence : Report report of the therapeutics and technology assessment subcommittee of the american academy of neurology by GOODIN, D. S, FROHMAN, E. M, HURWITZ, B, O'CONNOR, P. W, OGER, J. J, REDER, A. T, STEVENS, J. C

“…The clinical and radiologic impact of developing neutralizing antibodies (NAbs) to interferon beta (IFNbeta) while on this therapy for multiple sclerosis (MS)…”
Get full text

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS by MILLER, D. H, SOON, D, KAPPOS, L, HUTCHINSON, M, HAVRDOVA, E, LUBLIN, F. D, GIOVANNONI, G, WAJGT, A, RUDICK, R, LYNN, F, PANZARA, M. A, SANDROCK, A. W, FERNANDO, K. T, MACMANUS, D. G, BARKER, G. J, YOUSRY, T. A, FISHER, E, O'CONNOR, P. W, PHILLIPS, J. T, POLMAN, C. H

“…In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients…”
Get full text

Teriflunomide added to interferon-β in relapsing multiple sclerosis: A randomized phase II trial by FREEDMAN, M. S, WOLINSKY, J. S, SIMONSON, C, O'CONNOR, P. W, WAMIL, B, CONFAVREUX, C, COMI, G, KAPPOS, L, OLSSON, T. P, MILLER, A, BENZERDJEB, H, LI, H

“…To evaluate teriflunomide as add-on therapy to ongoing stable-dosed interferon-β (IFNβ) in patients with relapsing forms of multiple sclerosis (RMS). A total…”
Get full text

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks by Morrow, SA, O'Connor, PW, Polman, CH, Goodman, AD, Kappos, L, Lublin, FD, Rudick, RA, Jurgensen, S, Paes, D, Forrestal, F, Benedict, RHB

“…Background and Objectives: Brief cognitive tests to monitor cognitive impairment in patients with multiple sclerosis (MS) are needed. Methods: Performance on…”
Get full text

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis by BALCER, L. J, GALETTA, S. L, O'CONNOR, P. W, PHILLIPS, J. T, POLMAN, C. H, RADUE, E.-W, RUDICK, R. A, STUART, W. H, WAJGT, A, WEINSTOCK-GUTTMAN, B, WYNN, D. R, LYNN, F, CALABRESI, P. A, PANZARA, M. A, CONFAVREUX, C, GIOVANNONI, G, HAVRDOVA, E, HUTCHINSON, M, KAPPOS, L, LUBLIN, F. D, MILLER, D. H

“…To examine the effects of natalizumab on low-contrast letter acuity as a prespecified tertiary endpoint in two randomized clinical trials and to evaluate the…”
Get full text

Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion by Chen, J.T., Kuhlmann, T., Jansen, G.H., Collins, D.L, Atkins, H.L., Freedman, M.S., O’Connor, P.W., Arnold, D.L.

“…We present a new method for advanced image processing to separately quantify significant decreases and increases in the magnetization transfer ratio (MTR) of…”
Get full text

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses by O'CONNOR, P. W, LI, D, FREEDMAN, M. S, BAR-OR, A, RICE, G. P. A, CONFAVREUX, C, PATY, D. W, STEWART, J. A, SCHEYER, R

“…Teriflunomide, a dihydro-orotate dehydrogenase inhibitor, has immunomodulatory effects, including the ability to suppress experimental allergic…”
Get full text

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis by Polman, Chris H, O'Connor, Paul W, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Miller, David H, Phillips, J. Theodore, Lublin, Fred D, Giovannoni, Gavin, Wajgt, Andrzej, Toal, Martin, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…This placebo-controlled, randomized trial of patients with relapsing multiple sclerosis demonstrated benefits of natalizumab (an α 4 integrin antagonist) in…”
Get full text

Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects by O'CONNOR, P. W, GOODMAN, A, WILLMER-HULME, A. J, LIBONATI, M. A, METZ, L, MURRAY, R. S, SHEREMATA, W. A, VOLLMER, T. L, STONE, L. A

“…Relapses in multiple sclerosis (MS) can cause significant neurologic disability. Natalizumab (Antegren) is a humanized anti-alpha4-integrin antibody that…”
Get full text

Type I Diabetes and Multiple Sclerosis Patients Target Islet Plus Central Nervous System Autoantigens; Nonimmunized Nonobese Diabetic Mice Can Develop Autoimmune Encephalitis by Winer, Shawn, Astsaturov, Igor, Cheung, Roy K, Gunaratnam, Lakshman, Kubiak, Violetta, Cortez, Miguel A, Moscarello, Mario, O'Connor, Paul W, McKerlie, Colin, Becker, Dorothy J, Dosch, H.-Michael

“…Type I diabetes and multiple sclerosis (MS) are distinct autoimmune diseases where T cells target either islet or CNS self-proteins. Unexpectedly, we found…”
Get full text

Dune activity as a record of late Quaternary aridity in the Northern Kalahari: new evidence from northern Namibia interpreted in the context of regional arid and humid chronologies by Thomas, D.S.G., O'Connor, P.W., Bateman, M.D., Shaw, P.A., Stokes, S., Nash, D.J.

“…Sediments from presently vegetated linear dune ridges in the Caprivi Strip of northern Namibia are optically dated to assess the timing of dune building…”
Get full text

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL by Hutchinson, M., Kappos, L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Galetta, S. L., Havrdova, E., Lublin, F. D., Miller, D. H., O’Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E.-W., Rudick, R. A., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A.

“…The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFNβ)-1a in patients with…”
Get full text

Assessing disability progression with the Multiple Sclerosis Functional Composite by Rudick, RA, Polman, CH, Cohen, JA, Walton, MK, Miller, AE, Confavreux, C, Lublin, FD, Hutchinson, M, O’Connor, PW, Schwid, SR, Balcer, LJ, Lynn, F, Panzara, MA, Sandrock, AW

“…Background The initial Multiple Sclerosis Functional Composite (MSFC) proposal was a three-part composite of quantitative measures of ambulation, upper…”
Get full text

Pulmonary arteriovenous malformation: a rare, treatable cause of stroke in young adults by Retnakaran, R R, Faughnan, M E, Chan, R P, Pugash, R A, O'Connor, P W, Chow, C M

“…Pulmonary arteriovenous malformation (PAVM) predisposes affected patients to a significantly increased risk of stroke. Most commonly, PAVM is seen in patients…”
Get more information

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment by Polman, C H, Reingold, S C, Barkhof, F, Calabresi, P A, Clanet, M, Cohen, J A, Cutter, G R, Freedman, M S, Kappos, L, Lublin, F D, McFarland, H F, Metz, L M, Miller, A E, Montalban, X, O'Connor, P W, Panitch, H, Richert, J R, Petkau, J, Schwid, S R, Sormani, M P, Thompson, A J, Weinshenker, B G, Wolinsky, J S

“…The increasing number of established effective therapies for relapsing multiple sclerosis (MS) and emerging consensus for early treatment raise practical…”
Get full text

Ventricular enlargement in MS : One-year change at various stages of disease by DALTON, C. M, MISZKIEL, K. A, O'CONNOR, P. W, PLANT, G. T, RICE, G. P. A, MILLER, D. H

“…To investigate ventricular enlargement (VE) over 1 year at three different stages of multiple sclerosis (MS). A semi-automated technique for measuring VE was…”
Get full text

Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study by Doerner, M, Beckmann, K, Knappertz, V, Kappos, L, Hartung, H P, Filippi, M, O'Connor, P W, Arnason, B, Cook, S, Jeffery, D, Comi, G, Limmroth, V

“…In experimental autoimmune encephalomyelitis, inhibition of the renin-angiotensin system with angiotensin receptor blockers (ARBs) or angiotensin-converting…”
Get more information

Reducing clinical trial risk in multiple sclerosis by De Gasperis-Brigante, C.D, Parker, J.L, O’Connor, P.W, Bruno, T.R

“…Abstract Objective To determine the risk of clinical trial failure for new drugs in multiple sclerosis (MS) and to identify factors that could improve…”
Get full text

Infusion-related hypersensitivity reactions during natalizumab treatment by PHILLIPS, J. T, O'CONNOR, P. W, LYNN, F, PANZARA, M. A, SANDROCK, A. W, HAVRDOVA, E, HUTCHINSON, M, KAPPOS, L, MILLER, D. H, POLMAN, C. H, LUBLIN, F. D, GIOVANNONI, G, WAJGT, A

Get full text